In a UK patient taking lisdexamfetamine 60 mg daily with a morning dexamphetamine booster who has low drive and persistent low mood, what approved antidepressant options are recommended since bupropion (Wellbutrin) is not licensed for depression?

UK-Approved Antidepressant Options for Low Drive and Persistent Low Mood in a Patient on Lisdexamfetamine

For a UK patient on lisdexamfetamine 60 mg with low drive and persistent low mood, start with an SSRI (sertraline 50-200 mg daily or citalopram 10-40 mg daily) or SNRI (venlafaxine 75-225 mg daily), as these are first-line UK-licensed antidepressants with established efficacy for major depression. 1, 2

Why Not Bupropion in the UK

Bupropion (Wellbutrin) is not licensed as an antidepressant in the UK, despite being widely used in the US, Canada, and Europe for major depressive disorder 3. While it has demonstrated efficacy comparable to SSRIs and has unique benefits (activating properties, minimal sexual dysfunction, no weight gain) 4, 5, UK patients cannot access it for depression through standard NHS prescribing. The NHS repurposing medicines programme may eventually improve access, but this remains unavailable currently 3.

First-Line UK-Licensed Options

SSRIs (Selective Serotonin Reuptake Inhibitors)

Sertraline is particularly well-suited for this clinical scenario:

• Dosing: Start 25-50 mg daily, titrate to 200 mg daily as needed 6
• Advantages: Well-tolerated, fewer drug interactions than other SSRIs, less effect on metabolism of other medications 1
• Considerations: May cause diarrhea more than other antidepressants; monitor for activation/agitation in first 1-2 weeks 1

Citalopram is another reasonable first choice:

• Dosing: Start 10 mg daily, maximum 40 mg daily 6
• Advantages: Well-tolerated, straightforward dosing 1
• Cautions: QT prolongation risk—obtain baseline ECG if cardiac risk factors present; maximum dose reduced to 20 mg in patients >60 years 7

Fluoxetine (activating SSRI):

• Dosing: Start 10 mg every other morning, increase to 20 mg daily 6
• Advantages: Activating properties may help with low drive; very long half-life 6
• Cautions: Side effects may not manifest for weeks due to long half-life; more drug interactions via CYP450 inhibition 6

SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors)

Venlafaxine may be particularly beneficial for low drive/energy:

• Dosing: Start 37.5-75 mg daily, titrate to 150-225 mg daily over 2-4 weeks 8
• Advantages: Dual mechanism (serotonin + norepinephrine) may address low drive better than SSRIs alone; effective for treatment-resistant depression 8
• Cautions: Monitor blood pressure (can cause dose-dependent increases); requires gradual taper when discontinuing to avoid withdrawal syndrome 8, 7. Cardiac conduction abnormalities reported rarely—use caution if cardiac disease 8

Duloxetine:

• Dosing: Start 30 mg once daily for 1 week, then 60 mg once daily 8
• Advantages: Simple once-daily dosing; no clinically significant ECG or blood pressure changes; effective for depression with anxiety 8
• Cautions: Nausea common initially (reduced by starting at 30 mg) 8

Critical Monitoring and Safety Considerations

Interaction with Lisdexamfetamine

Monitor cardiovascular parameters closely: Both lisdexamfetamine and certain antidepressants (particularly SNRIs) can increase blood pressure and heart rate. Check blood pressure at baseline, week 1-2, and regularly thereafter 9.

Seizure Risk

The patient is already on a high dose of lisdexamfetamine (60 mg) plus dexamphetamine booster. Avoid medications that lower seizure threshold:

• TCAs (tricyclic antidepressants) should be avoided or used with extreme caution 6
• If considering any antidepressant, ensure no history of seizures or brain pathology 10

Suicidality Monitoring

Assess within 1-2 weeks of starting treatment and regularly thereafter, especially in the first 1-2 months when suicide attempt risk is highest 1. SSRIs are associated with increased risk of nonfatal suicide attempts (OR 1.57-2.25) 1.

Sexual Dysfunction

If sexual function is a concern (common with SSRIs):

• Paroxetine has highest rates of sexual dysfunction among SSRIs 1
• Sertraline and fluoxetine have intermediate rates 1
• Consider this in medication selection, though bupropion (unavailable in UK for depression) would have been ideal for avoiding this issue 1

Treatment Algorithm

1. Week 0: Start sertraline 50 mg daily OR citalopram 10 mg daily OR venlafaxine 75 mg daily

   • Obtain baseline blood pressure, heart rate, ECG if indicated
   • Screen for bipolar disorder history (antidepressants can trigger mania) 9

2. Week 1-2: Assess for:

   • Suicidal ideation or worsening depression
   • Activation, agitation, or unusual behavioral changes
   • Blood pressure/heart rate changes
   • Tolerability (nausea, insomnia, anxiety)

3. Week 4-6: Assess response

   • If partial response: Increase dose (sertraline to 100-150 mg, citalopram to 20-30 mg, venlafaxine to 150 mg)
   • If no response: Consider switching antidepressant class

4. Week 6-8: Reassess at target dose

   • If <30% symptom reduction: Switch to alternative first-line medication (different class) 2
   • If partial response: Continue titration to maximum tolerated dose
   • If good response: Continue treatment for at least 9 months before considering dose reduction 6

Second-Line Options if First-Line Fails

If SSRIs/SNRIs fail after adequate trial (6-8 weeks at therapeutic dose):

Mirtazapine:

• Dosing: Start 7.5 mg at bedtime, increase to 30 mg 6
• Advantages: Potent, well-tolerated, promotes sleep and appetite 6
• Cautions: Weight gain, sedation

Tricyclic Antidepressants (use with caution):

• Nortriptyline: 10 mg at bedtime, maximum 40 mg/day (divided dosing) 6
• Advantages: May be activating (reduces apathy), therapeutic blood level monitoring available 6
• Cautions: Cardiac toxicity risk—obtain screening ECG if >40 years; avoid if cardiac disease; monitor for tachycardia; increased seizure risk when combined with stimulants 8, 6

Common Pitfalls to Avoid

• Underdosing: Many patients require maximum approved doses for response—don't stop at starting doses 1
• Inadequate trial duration: Minimum 6-8 weeks at therapeutic dose required before declaring treatment failure 1, 2
• Ignoring cardiovascular monitoring: Critical with stimulant + antidepressant combination 9
• Missing bipolar disorder: Screen for personal/family history before starting—antidepressants can precipitate mania 9
• Abrupt discontinuation: Taper over 10-14 days to avoid withdrawal, especially with venlafaxine 8, 6